

## 2020 Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR Scientific Program:

Recommended Plenary and Concurrent Sessions February 19-23, 2020 | Orlando, FL

## **ADMINISTRATORS**

Session Type and Date	Session Title and Description
Concurrent 2 (Wed 2/19)	<b>Health Economics in CAR-T: Patient, Provider, and Policy Implications of the Costs of Our Therapies</b> This session will provide three different perspectives - provider, patient, and policy - on the economic changes CAR-T has brought to the health care system.
Plenary 3 (Thurs 2/20)	Alternative Donor Transplant In this session we will focus on the use of alternative donors for allogeneic transplantation. We will discuss the pros and cons of mismatched unrelated, haploidentical and cord blood transplants. We will recognize the clinical challenges in these different fields and strategies instituted by transplant centers to improve clinical outcomes. We will review the early days, current advantages and challenges, and finally promising efforts to further strengthen their role as a highly desired stem cell sources in patients undergoing hematopoietic stem cell transplantation.
Plenary 4 (Fri 2/21)	ASTCT President's Symposium: Personalizing Survivorship Care in Transplant and Cell Therapy  Late complications are a well-recognized sequelae of hematopoietic cell transplantation. Research has led to better understanding of the pathogenesis, risk factors, prevention and management of late effects. Many principles of post-transplant survivorship care can be applied to the nascent field of cell therapy. This session will review recent advances in transplantation late effects. Presentations will focus on current knowledge about biology of late complications following transplantation, the use of health technology tools to personalize survivorship care and facilitate self-management in transplant recipients, and the role of patient reported outcomes in research and clinical care. Speakers will also provide examples of the application of these aspects of survivorship towards recipients of cellular therapies.
Plenary 6 (Sun 2/23)	ASTCT/CIBMTR/EBMT Joint Session: Bridging the gap in BMT and cellular therapy between North America and Europe  This joint session organized by the ASTCT, the CIBMTR and the EBMT will review areas of strength and successful collaborations in blood and marrow transplantation and cellular therapy between North America and Europe, and will lay the foundation for future collaborative work in this area. First topic in this session will highlight differences and similarities in transplantation practices in the two geographical areas, describe their rationale and impact on patient outcomes, and identify areas where best practices could potentially be translated across countries and continents. A second topic will review the current landscape and penetration of CAR-T cell therapies in North America and Europe and will discuss challenges faced in the areas of clinical trials, commercial implementation and regulatory issues. This topic will also include discussion of successful practices and policies that countries in the process of starting CAR-T cell therapies can consider, including their economic aspects and costs. The last speaker in this session will highlight areas of successful collaboration in registry research and clinical trials between North America and Europe in blood and marrow transplantation and cellular therapy. This topic will also include discussion of opportunities for enhancing collaborative research in this area between the two continents.